全文获取类型
收费全文 | 58815篇 |
免费 | 3544篇 |
国内免费 | 1608篇 |
专业分类
耳鼻咽喉 | 436篇 |
儿科学 | 1040篇 |
妇产科学 | 727篇 |
基础医学 | 5019篇 |
口腔科学 | 1272篇 |
临床医学 | 5327篇 |
内科学 | 6255篇 |
皮肤病学 | 535篇 |
神经病学 | 3525篇 |
特种医学 | 1413篇 |
外国民族医学 | 6篇 |
外科学 | 5931篇 |
综合类 | 10843篇 |
现状与发展 | 1篇 |
一般理论 | 4篇 |
预防医学 | 5357篇 |
眼科学 | 1059篇 |
药学 | 5142篇 |
111篇 | |
中国医学 | 8147篇 |
肿瘤学 | 1817篇 |
出版年
2024年 | 185篇 |
2023年 | 988篇 |
2022年 | 1804篇 |
2021年 | 2428篇 |
2020年 | 2170篇 |
2019年 | 2308篇 |
2018年 | 2029篇 |
2017年 | 1878篇 |
2016年 | 1753篇 |
2015年 | 1514篇 |
2014年 | 3661篇 |
2013年 | 3344篇 |
2012年 | 3291篇 |
2011年 | 4044篇 |
2010年 | 3681篇 |
2009年 | 2747篇 |
2008年 | 2524篇 |
2007年 | 2726篇 |
2006年 | 2545篇 |
2005年 | 2099篇 |
2004年 | 1726篇 |
2003年 | 1595篇 |
2002年 | 1111篇 |
2001年 | 1007篇 |
2000年 | 828篇 |
1999年 | 766篇 |
1998年 | 606篇 |
1997年 | 588篇 |
1996年 | 459篇 |
1995年 | 512篇 |
1994年 | 471篇 |
1993年 | 391篇 |
1992年 | 383篇 |
1991年 | 333篇 |
1990年 | 315篇 |
1989年 | 294篇 |
1988年 | 305篇 |
1987年 | 244篇 |
1986年 | 233篇 |
1985年 | 489篇 |
1984年 | 475篇 |
1983年 | 360篇 |
1982年 | 407篇 |
1981年 | 405篇 |
1980年 | 388篇 |
1979年 | 336篇 |
1978年 | 298篇 |
1977年 | 264篇 |
1976年 | 211篇 |
1975年 | 123篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
目的 对比研究朝鲜淫羊藿酸性多糖酯化还原前后的理化特性,并探讨其改善油酸诱导的肝癌HepG2细胞脂质堆积活性的差异。方法 采用高效凝胶渗透色谱法测定朝鲜淫羊藿酸性多糖(EFPA)的均一性和分子量,高效液相色谱法测定EFPA和酯化还原后朝鲜淫羊藿酸性多糖(EFPA-R)的单糖组成;采用油酸(OA)处理HepG2细胞诱导建立脂质蓄积模型,不同浓度EFPA与EFPA-R(10、30、100、300 μg·mL-1)分别和OA共同作用于细胞24 h,采用CCK-8试剂盒测定细胞存活率,油红O染色观察细胞内脂滴蓄积情况,并采用试剂盒测定细胞内总胆固醇(TC)、甘油三酯(TG)含量。结果 EFPA为成分均一的多糖组分,分子量为125.8 kDa,由甘露糖、葡萄糖、半乳糖、葡萄糖醛酸和阿拉伯糖组成,摩尔比为1.7∶7.4∶1.4∶1.8∶1.0,葡萄糖占比最大,EFPA-R由甘露糖、葡萄糖、半乳糖和阿拉伯糖组成,摩尔比为0.8∶10.6∶2.1∶1.0;在10-300 μg·mL-1范围内,EFPA和EFPA-R对HepG2细胞的抑制作用较弱,作为给药浓度;与空白组相比,模型组细胞中TC、TG含量显著升高(P < 0.01),细胞内红色脂滴显著增多,与模型组相比,EFPA可显著降低细胞中TC、TG含量(P < 0.01),明显减少细胞内红色脂滴(P < 0.05或P < 0.01),EFPA-R干预后细胞则无明显变化。结论 EFPA可明显改善HepG2细胞脂质堆积情况,且呈现剂量依赖性,而半乳糖醛酸(GalA)的存在可能是其抑制HepG2细胞脂质蓄积的关键因素。 相似文献
2.
3.
4.
5.
6.
《Journal of vascular and interventional radiology : JVIR》2022,33(4):359-367.e8
PurposeTo review and to compare indirectly the outcomes of minimally invasive therapies for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia.Materials and MethodsA literature search via Medline and Cochrane Central databases was completed for randomized control studies published between January 2000 to April 2020 for the following therapies: Rezum, Urolift, Aquablation, and prostatic artery embolization (PAE). Data on the following variables were included: International prostate symptom score (IPSS), maximum urinary flow rate, quality of life, and postvoid residual (PVR). Standard mean differences between treatments were compared through a meta-analysis using transurethral resection of the prostate (TURP) to assess differences in treatment effect.ResultsThere was no significant difference in outcomes between therapies for IPSS at the 3, 6, and 12-month follow ups. Although outcomes for Rezum were only available out to 3 months, there were no consistently significant differences in outcomes when comparing Aquablation versus PAE versus Rezum. TURP PVR was significantly better than Urolift at 3, 6, and 12 months. No significant differences in minor or major adverse events were noted.ConclusionAlthough significant differences in outcomes were limited, Aquablation and PAE were the most durable at 12 months. PAE has been well studied on multiple randomized control trials with minimal adverse events while Aquablation has limited high quality data and has been associated with bleeding-related complications. 相似文献
7.
《Journal of pediatric surgery》2023,58(5):856-861
Background/PurposeA small number of Hirschsprung disease (HD) patients develop inflammatory bowel disease (IBD)-like symptoms after pullthrough surgery. The etiology and pathophysiology of Hirschsprung-associated IBD (HD-IBD) remains unknown. This study aims to further characterize HD-IBD, to identify potential risk factors and to evaluate response to treatment in a large group of patients.MethodsRetrospective study of patients diagnosed with IBD after pullthrough surgery between 2000 and 2021 at 17 institutions. Data regarding clinical presentation and course of HD and IBD were reviewed. Effectiveness of medical therapy for IBD was recorded using a Likert scale.ResultsThere were 55 patients (78% male). 50% (n = 28) had long segment disease. Hirschsprung-associated enterocolitis (HAEC) was reported in 68% (n = 36). Ten patients (18%) had Trisomy 21. IBD was diagnosed after age 5 in 63% (n = 34). IBD presentation consisted of colonic or small bowel inflammation resembling IBD in 69% (n = 38), unexplained or persistent fistula in 18% (n = 10) and unexplained HAEC >5 years old or unresponsive to standard treatment in 13% (n = 7). Biological agents were the most effective (80%) medications. A third of patients required a surgical procedure for IBD.ConclusionMore than half of the patients were diagnosed with HD-IBD after 5 years old. Long segment disease, HAEC after pull through operation and trisomy 21 may represent risk factors for this condition. Investigation for possible IBD should be considered in children with unexplained fistulae, HAEC beyond the age of 5 or unresponsive to standard therapy, and symptoms suggestive of IBD. Biological agents were the most effective medical treatment.Level of EvidenceLevel 4 相似文献
8.
9.
10.
Tonya J.H. White 《Journal of the American Academy of Child and Adolescent Psychiatry》2019,58(11):1042-1050